For research and educational purposes only. Not medical advice.
Glutathione Reference
Educational, not medical advice reference for Glutathione: Longevity, Recovery; regulatory status, evidence posture, source review, and schedule…
Reference summary
Glutathione is the endogenous tripeptide (gamma-glutamyl-cysteinyl-glycine) and the cell's principal intracellular antioxidant. Oral glutathione bioavailability is poor because of intestinal hydrolysis; injectable preparations bypass that limitation. The Hauser 2009 Movement Disorders double-blind pilot of intravenous glutathione in early Parkinson disease reported a modest non-significant improvement in motor symptoms. Other small open-label series have reported mixed signals. No large outcome trial supports the community-cited longevity, skin-lightening, or detox indications.
Regulatory and posture
- Categories
- Longevity, Recovery
- Aliases
- GSH, L-glutathione, Reduced glutathione, IV glutathione, Glutathione infusion, SubQ glutathione
- Evidence posture
- translational - Endogenous antioxidant biology is real; injectable-glutathione human evidence for the community-cited indications is limited to small trials and open-label series. Compounded injection products are not FDA-approved and sterility / dose-accuracy depend on the compounder. Serious adverse events (anaphylaxis, Stevens-Johnson syndrome) have been reported with skin-lightening intravenous use.
- Regulatory status
- No FDA-approved injectable glutathione drug label exists for the anti-aging, skin-lightening, liver-detox, or hangover-recovery indications the product is marketed for. Compounded intravenous and subcutaneous glutathione preparations are sold by IV-therapy clinics and research-chemical sellers. The US FDA has flagged compounded preparations in its peptide-compounding safety communications, and the Philippines FDA issued a 2011 public warning against intravenous glutathione for skin whitening after serious adverse-event reports.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- PubMed Hauser 2009 Movement Disorders: randomized double-blind pilot of intravenous glutathione in early Parkinson disease (PMID 19353681)
- PubMed search: intravenous glutathione human literature
- ClinicalTrials.gov search: intravenous glutathione studies
Related tools
- Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
- BAC water calculator - Solve BAC water volume for a target concentration.
- Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
- Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.